Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio20.80
Quick Ratio20.80
Price-To-Earnings
Trailing P/E Ratio-19.56
Forward P/E Ratio8.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 million
Price / Sales580.71
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book5.52
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-3,300.12%
Return on Equity-26.20%
Return on Assets-24.58%
Miscellaneous
Employees18
Outstanding Shares173,080,000
Market Cap$626.55
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biopharmaceutical company had revenue of $0.32 million for the quarter. Geron had a negative net margin of 3,300.12% and a negative return on equity of 26.20%. During the same quarter last year, the company earned ($0.05) EPS. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
5 Wall Street analysts have issued 12-month price objectives for Geron's shares. Their predictions range from $4.00 to $7.00. On average, they expect Geron's share price to reach $5.5833 in the next year. This suggests a possible upside of 55.5% from the stock's current price. View Analyst Ratings for Geron.
What is the consensus analysts' recommendation for Geron?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Geron?
Geron saw a increase in short interest in June. As of June 29th, there was short interest totalling 52,712,240 shares, an increase of 18.2% from the June 15th total of 44,580,747 shares. Based on an average daily trading volume, of 4,769,004 shares, the short-interest ratio is currently 11.1 days. Approximately 30.6% of the company's stock are sold short. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH) and Phibro Animal Health (PAHC).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
- Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
- Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
- Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)
Has Geron been receiving favorable news coverage?
News articles about GERN stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Geron earned a media sentiment score of 0.06 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $3.59.
How big of a company is Geron?
Geron has a market capitalization of $626.55 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
